Sanofi

Sanofi. It is a global biopharmaceutical company headquartered in Paris, France, and is a constituent of the CAC 40 index. The company is engaged in the research, development, manufacturing, and marketing of therapeutic solutions across several key disease areas. Its extensive portfolio includes treatments for diabetes, cardiovascular diseases, oncology, immunology, and rare diseases.

History

The company's origins trace back to 1973 with the founding of its initial entity. A major formative step occurred in 1999 with the merger of Total's pharmaceutical subsidiary with Elf Aquitaine's healthcare interests, creating a significant European player. A pivotal transformation happened in 2004 through a three-way merger with Aventis, a giant formed from the earlier union of Hoechst and Rhône-Poulenc, which was one of the largest deals in pharmaceutical industry history. Further expansion came with the 2011 acquisition of Genzyme, a leader in biotechnology for rare diseases, and the 2018 purchase of Bioverativ, strengthening its hematology franchise. The company has also engaged in significant divestments, such as selling its animal health business to Boehringer Ingelheim in 2017 and its European generics division to Advent International.

Business segments

Its operations are organized into three primary business units. The Specialty Care segment focuses on immunology, rare diseases, neurology, and oncology, driven largely by assets from the Genzyme and Bioverativ acquisitions. The Vaccines unit is one of the world's largest, producing immunizations for influenza, polio, pertussis, and meningitis, and played a critical role during the COVID-19 pandemic. The General Medicines division encompasses established prescription drugs and consumer healthcare products, including major franchises in diabetes and cardiovascular therapeutics, though this segment has faced pressure from generic competition.

Products

The company markets a wide array of pharmaceutical and vaccine products. Its diabetes portfolio has historically been anchored by Lantus, a long-acting insulin analog, and Toujeo. In rare diseases, it offers treatments for Gaucher's disease and Fabry disease inherited from Genzyme. The vaccines division produces Fluzone for influenza and Pentacel for pediatric combination vaccination. Other notable products include Dupixent, developed in partnership with Regeneron for atopic dermatitis and asthma, and Aubagio for multiple sclerosis. Its consumer healthcare arm sells over-the-counter brands like Allegra and Icy Hot.

Research and development

Its research and development strategy is centered on leveraging immunology and advanced technologies to address unmet medical needs. Key focus areas include immunology and inflammation, with Dupixent serving as a cornerstone, oncology through platforms like antibody-drug conjugates, and vaccines utilizing novel mRNA and adjuvant technologies. The company operates major R&D hubs in Vitry-sur-Seine, France, and Cambridge, United States. It actively pursues external innovation through collaborations with biotechnology firms like Translate Bio and Kymab, and academic institutions such as the University of Oxford.

Corporate affairs

The company is led by a Chief Executive Officer and governed by a Board of Directors. Its global headquarters are located in Paris, with significant operations in Bridgewater, United States. It is a publicly traded entity listed on Euronext Paris and the NASDAQ. The firm engages in numerous public-private partnerships, including long-standing collaborations with the World Health Organization on polio and yellow fever eradication programs. It is also a signatory to the United Nations Global Compact and publishes annual reports on its environmental and social governance performance.

Controversies

The company has faced several legal and ethical challenges over the years. It was involved in litigation concerning the sleep medication Ambien, with allegations of downplaying side effects. Its diabetes drug Lantus was the subject of studies and litigation probing potential cancer risks. In 2018, it reached a settlement with the U.S. Department of Justice over kickback allegations related to its Multiple Sclerosis drug Lemtrada. More recently, its COVID-19 vaccine developed with GlaxoSmithKline faced delays and reported efficacy challenges during clinical trials, impacting its rollout. Past operations have also drawn criticism from groups like Public Citizen and Médecins Sans Frontières regarding drug pricing and patent practices.